Artax Biopharma

Artax Biopharma

Artax Biopharma is a clinical stage biotechnology company that develops novel treatments for autoimmune diseases.

The lead product, AX-158, is a first-in-class, oral small molecule that inhibits Nck’s binding to the T cell receptor (TCR).  Through this novel mechanism, it selectively modulates Nck’s amplification of the TCR signal, resulting in a lower T Cell activation and lower T Cell response.

Location: Cambridge, USA

Sound contact: Casper Breum (Board Director) and Ester Sklarsky (Board Observer)


Artax expands their SAB with two experts in T-Cell-Mediated Diseases

11 April 2022, Artax Biopharma Closes Financing to Advance Clinical Stage First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases